We are live on ! Find out more
VINC

Vincerx Pharma, Inc. Common Stock
VINC

Delisted

VINC was delisted on the 22nd of April, 2025.

Back to rankings

55 hedge funds and large institutions have $157M invested in Vincerx Pharma, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 29 increasing their positions, 6 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

383% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 6

2% less funds holding

Funds holding: 56 → 55 (-1)

10% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 10

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

37% less capital invested

Capital invested by funds: $249M → $157M (-$92.1M)

Holders
55
Holders Change
-1
Holders Change %
-1.79%
% of All Funds
0.85%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
9
Increased
29
Reduced
6
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$3.42M
2
CC
Clearline Capital
New York
+$1.63M
3
AAA
Affinity Asset Advisors
New York
+$1.63M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.49M
5
KCM
Kingdon Capital Management
New York
+$999K

Top Sellers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
-$7.28M
2
ACP
Acuta Capital Partners
California
-$4.2M
3
MIM
Monashee Investment Management
Massachusetts
-$3.23M
4
IC
Ikarian Capital
Texas
-$3.22M
5
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$2.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
SRC
1
Sage Rhino Capital
California
$16.5M – – –
RCMNY
2
Rubric Capital Management (New York)
New York
$16.2M +$3.42M +13,692 +21%
DM
3
Deerfield Management
New York
$14.1M – – –
AAA
4
Affinity Asset Advisors
New York
$11.6M +$1.63M +6,518 +13%
TCM
5
Tang Capital Management
California
$10.5M – – –
RSCM
6
Rock Springs Capital Management
Maryland
$8.25M +$111K +445 +1%
BlackRock
7
BlackRock
New York
$7.87M +$551K +2,209 +6%
Holocene Advisors
8
Holocene Advisors
New York
$7.73M – – –
RI
9
RTW Investments
New York
$7.55M -$109K -438 -1%
SFM
10
Sphera Funds Management
Israel
$7.34M +$818K +3,279 +10%
Vanguard Group
11
Vanguard Group
Pennsylvania
$6.67M +$1.49M +5,966 +22%
Citadel Advisors
12
Citadel Advisors
Florida
$6.37M -$18K -72 -0.2%
Wellington Management Group
13
Wellington Management Group
Massachusetts
$4.02M +$765K +3,066 +18%
KCM
14
Kingdon Capital Management
New York
$3.92M +$999K +4,005 +26%
Point72 Asset Management
15
Point72 Asset Management
Connecticut
$3.51M – – –
SSA
16
Schonfeld Strategic Advisors
New York
$2.98M +$270K +1,083 +8%
SM
17
Sabby Management
Florida
$2.64M +$735K +2,944 +29%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$2.5M +$345K +1,383 +13%
BBA
19
Baker Bros. Advisors
New York
$2.46M – – –
State Street
20
State Street
Massachusetts
$1.8M +$233K +932 +12%
Northern Trust
21
Northern Trust
Illinois
$1.46M +$289K +1,159 +19%
LFCM
22
Long Focus Capital Management
Puerto Rico
$1.43M +$1.75M +7,010 New
CC
23
Clearline Capital
New York
$1.33M +$1.63M +6,543 New
PVI
24
Pura Vida Investments
New York
$1.1M +$603K +2,418 +81%
SCM
25
Sio Capital Management
New York
$1.04M – – –
1
2 3

VINC Hedge Fund Activity: Q4 2021 in Review

55 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q4 2021, worth a combined $157M — down 37% from $249M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of VINC and 9 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 29 added.

The largest buyer was Rubric Capital Management (New York), adding an estimated $3.42M. The largest seller was Boxer Capital, exiting entirely with an estimated $7.28M sold.

  • 55 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q4 2021, down from 56 in Q3 2021.
  • Funds reported $157M of Vincerx Pharma, Inc. Common Stock stock for Q4 2021, down 37% quarter-over-quarter.
  • 9 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q4 2021 and 10 closed out, a net change of -1 holder.
  • The largest Vincerx Pharma, Inc. Common Stock buyer in Q4 2021 was Rubric Capital Management (New York), an estimated $3.42M added.
  • The largest Vincerx Pharma, Inc. Common Stock seller in Q4 2021 was Boxer Capital, an estimated $7.28M sold.

Based on aggregated 13F filings for Q4 2021.